Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir

SUPPRESS Did Not Achieve Primary Endpoint for Prevention of Clinically Significant CMV Infection After HCT Detailed Data Analysis to Follow Company to Hold Conference Call Today at 8:30 a.m. ET DURHAM, N.C., Dec. 28, 2015 -- (Healthcare Sales & Ma... BiopharmaceuticalsChimerix, brincidofovir, cytomegalovirus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news